NEURALINK 2025: - Received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments. - Launched its first clinical trial in the Middle East (UAE-PRIME) at Cleveland Clinic Abu Dhabi in partnership with the Department of Health Abu Dhabi. - Raised $650 million in Series E funding, led by investors including ARK Invest, Sequoia Capital, and Founders Fund, valuing the company at approximately $9 billion. - Launched clinical trials in the United Kingdom in partnership with University College London Hospitals and Newcastle Hospitals. - Performed its first procedures outside the United States, implanting devices in two patients with cervical spinal cord injuries at Toronto's University Health Network in Canada. - Completed two surgeries in Canada, marking the first non-US procedures. - The first UK participant, Paul, received an implant and controlled a computer with thoughts hours after surgery at University College London Hospitals. - Convoy project testing with participants controlling robotic arms with their BCIs. - Introduced an upgraded next-generation surgical robot with improved electrode thread insertion time of 1.5 seconds per thread, greater insertion depths over 50mm, enhances compatibility with 99% of anatomical variations globally, and lowers manufacturing costs for needle cartridges by 95%. - Announced goals for faster LASIK-like implant procedures in minutes and emphasized flexible electrode threads for safer neuron placement. - As of now it is estimated that Neuralink as 20 participants. Know are Noland Arbaugh (@ModdedQuad), Alex Conley (@Bcidesign), Bradford Smith (@ALScyborg), Michael Melgarejo, RJ Tanner, Rob Greiner (@greiner_ro52817), Jake Schneider (@PairedWith_P7), Nick Wray (@Telepath_8), Audrey Crews (@NeuraNova9), Paul, and Jon L. Noble (@CheckCanopy).

When I was first injured in 2003 at just 20 years old and full of dreams for the future, the senior consultant sat my parents and me down and delivered words that shattered our world: despite my youth, I would likely not live to see 52. I can still feel the weight of that moment—the devastation in my parents’ eyes, the sudden darkness that seemed to eclipse everything ahead. That prognosis hung over us like a shadow for years, shaping how we lived, grieved, and hoped in quiet, limited ways. But receiving the Neuralink N1 brain-computer interface has profoundly shifted something deep within me. We’re undeniably in the early days of this technology—it’s imperfect, experimental, and full of unknowns—but there’s an indescribable difference now. A spark of possibility that defies explanation. For the first time in a long while, I feel a genuine sense of forward momentum, not just survival, but true potential unfolding. It’s changed my mindset entirely, replacing resignation with wonder about what might come next—not just for me, but for others facing similar sentences. This isn’t just about regaining control; it’s about reclaiming

🇬🇧 We’re excited to announce our first participant in the UK! Paul, who is paralyzed due to motor neuron disease, received his Neuralink implant at @uclh earlier this month and was able to control a computer with his thoughts just hours after surgery.

The first UK patient to receive a @neuralink implant used a computer just by using his thoughts hours after his surgery at UCLH. Paul, who has motor neurone disease, joined the GB-PRIME study and is now exploring use of the technology in his daily life: buff.ly/QgoWtlt

Hirschbichler et al. find that DBS-induced VTA inhibition does not impair reinforcement learning, but does lead to more strategic betting behaviour. They propose that the VTA may help sustain reward-driven behaviours over time. tinyurl.com/ywym2u7d

Joined by perhaps the greatest minds in neuroimaging for functional surgery in Neurosurgery @HarithAkram and Neurology @andreashorn_ at #MayoClinicFlorida Rhoton-de Oliveira Functional Course! #DBS